Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor

S. Ben-Horin*, B. Ungar, U. Kopylov, A. Lahat, M. Yavzori, E. Fudim, O. Picard, Y. Peled, R. Eliakim, E. Del Tedesco, S. Paul, X. Roblin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Background: Data on combination-biologic treatment in (IBD) are still scant. Aim: To explore outcomes of patients co-exposed to anti-TNF and vedolizumab. Methods: Patients starting vedolizumab having measurable anti-TNF levels after recently stopping adalimumab/infliximab (‘VDZ-aTNF’ group), were compared with control vedolizumab patients in a retrospective 1:2 matched case-control study. Results: Seventy-five patients were included (25 VDZ-aTNF, 50 VDZ). Adverse events were experienced by 9/25 VDZ-aTNF compared to 13/50 VDZ patients (P = 0.4, follow-up 14 weeks in all). Week 14 clinical remission was attained in 10/25 (40%) of VDZ-aTNF patients versus 23/50 (46%) of VDZ patients (OR = 0.8, 95% CI 0.3-2.1, P = 0.6) and clinical response in 19/25 (76%) versus 39/50 (78%) respectively (OR = 0.9, 95% CI 0.3-2.7, P = 0.8). Corticosteroid-free remission and corticosteroid-free response were experienced by 30% and 54%, respectively, of the entire cohort, and were similar between the two groups. Vedolizumab drug concentrations at week 2, 6 and 14 were similar among VDZ-aTNF and VDZ patients (P > 0.5). Multi-variable analysis showed independent association of some vedolizumab drug-levels time-points with baseline albumin and weight, but not with anti-TNF co-exposure. In a prospective study of a separate cohort of patients starting infliximab (n = 12), the percentage of α4β7+ memory T cells, slightly but nonsignificantly increased throughout weeks 0, 2 to 14 (26 ± 2.3%, 27.8 ± 2.9%, 29.5 ± 2.6% respectively, P = 0.06). Conclusions: Vedolizumab/anti-TNF co-exposure did not generate new safety signals during 14-weeks induction, nor did it reduce efficacy or alter vedolizumab pharmacokinetics. These observations may aid the design of future co-biologics trials and also suggest that a deliberate waiting-interval between anti-TNF cessation and subsequent vedolizumab initiation may not be warranted.

Original languageEnglish
Pages (from-to)1117-1125
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Issue number8
StatePublished - Apr 2018


FundersFunder number
Chaim Sheba Medical Center
Leona M. and Harry B. Helmsley Charitable Trust


    Dive into the research topics of 'Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor'. Together they form a unique fingerprint.

    Cite this